1 Department of Radiology, Duke University Medical Center, Erwin Rd, Box 3808, Durham, NC 27710.
AJR Am J Roentgenol. 2014 May;202(5):W466-74. doi: 10.2214/AJR.13.11450.
The objective of our study was to assess the accuracy of iodine-related attenuation and iodine quantification as imaging biomarkers of iodine uptake in renal lesions on a single-phase nephrographic image with dual-energy MDCT.
Fifty-nine patients (41 men, 18 women; age range, 28-84 years) with 80 renal lesions underwent contrast-enhanced dual-energy CT during the nephrographic phase of enhancement. Renal lesions were characterized as enhancing or nonenhancing on color-coded iodine overlay maps using iodine-related attenuation (in Hounsfield units) and iodine quantification (in milligrams per milliliter). For iodine-related attenuation the iodine uptake thresholds of 15 and 20 HU were tested; a threshold of 0.5 mg/mL was used for iodine quantification. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of iodine-related attenuation and iodine quantification were calculated from chi-square tests of contingency with histopathology or imaging follow-up as the reference standard. The 95% CIs were calculated from binomial expression. Differences in sensitivity and specificity were assessed by means of McNemar analysis.
A significant difference in sensitivity and specificity was found between iodine-related attenuation with the thresholds of 15 HU (sensitivity, 91.4%; specificity, 93.3%; PPV, 91.4%; NPV, 93.3%) and 20 HU (sensitivity, 77.1%; specificity, 100%; PPV, 100%; NPV, 84.9%) (p = 0.008) and between iodine quantification (sensitivity, 100%; specificity, 97.7%; PPV, 97.2%; NPV, 100%) and iodine-related attenuation with a threshold of 20 HU (p = 0.004). No significant difference in sensitivity and specificity was found between iodine quantification and iodine-related attenuation with a threshold of 15 HU.
Contrast-enhanced dual-energy MDCT with iodine-related attenuation and iodine quantification allows accurate evaluation of iodine uptake in renal lesions on a single-phase nephrographic image.
本研究的目的是评估双能 MDCT 单期肾实质期图像碘相关衰减和碘定量作为碘摄取的成像生物标志物的准确性。
59 例(男 41 例,女 18 例;年龄 28-84 岁)80 个肾脏病变患者行增强双能 CT 肾实质期扫描。使用碘相关衰减(HU)和碘定量(mg/ml)彩色编码碘覆盖图对肾脏病变进行强化或非强化的特征描述。碘相关衰减采用 15 和 20 HU 的碘摄取阈值进行测试;碘定量采用 0.5mg/ml 的阈值。通过卡方检验和组织病理学或影像学随访作为参考标准计算碘相关衰减和碘定量的敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV)。95%CI 通过二项式表达计算。采用 McNemar 分析评估敏感性和特异性的差异。
15 HU 碘相关衰减(敏感性 91.4%,特异性 93.3%,PPV 91.4%,NPV 93.3%)和 20 HU 碘相关衰减(敏感性 77.1%,特异性 100%,PPV 100%,NPV 84.9%)之间的敏感性和特异性存在显著差异(p=0.008),碘定量(敏感性 100%,特异性 97.7%,PPV 97.2%,NPV 100%)与 20 HU 碘相关衰减(p=0.004)之间的敏感性和特异性也存在显著差异。碘定量与 15 HU 碘相关衰减之间的敏感性和特异性无显著差异。
增强双能 MDCT 联合碘相关衰减和碘定量可准确评估单期肾实质期图像中肾脏病变的碘摄取。